Valuation: Relay Therapeutics, Inc.

Market Cap 4.08B 3.58B 3.3B 3.07B 5.79B 388B 5.91B 39.64B 15.36B 190B 15.31B 14.98B 662B P/E 2026 *
-12.2x
P/E 2027 * -11.9x
Enterprise Value 3.79B 3.32B 3.06B 2.85B 5.38B 360B 5.49B 36.8B 14.26B 177B 14.21B 13.91B 615B EV / Sales 2026 *
302x
EV / Sales 2027 * 236x
Free-Float
93.62%
Yield 2026 *
-
Yield 2027 * -
1 day-4.25%
1 week-0.28%
Current month-3.96%
1 month+26.02%
3 months+66.85%
6 months+119.68%
Current year+112.41%
1 week 17.62
Extreme 17.62
19.93
1 month 12.92
Extreme 12.925
19.93
Current year 7.01
Extreme 7.01
19.93
1 year 3.02
Extreme 3.025
19.93
3 years 1.78
Extreme 1.775
19.93
5 years 1.78
Extreme 1.775
38.6
10 years 1.78
Extreme 1.775
64.37
Manager TitleAgeSince
Chief Executive Officer 52 2017-02-28
Director of Finance/CFO 49 2018-03-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 54 2015-05-03
Director/Board Member 66 2016-06-30
Director/Board Member 52 2017-02-28
Date Insider Type Main position Quantity % Market Cap.
06-21Fiscal year

Chief Technology Officer

280,368 0.1463%
06-21Sell

Chief Financial Officer

-526,055 0.2746%
06-08Free

Director

32,947 0.0172%
Change 5-day change 1-year change 3-year change Capi.($)
-4.17%-0.28%+410.51%+41.94% 4.08B
+3.08%+6.47%-0.25%+6.27% 47.18B
-0.28%+9.44%+403.63%+592.47% 39.82B
+5.16%+9.53%+25.03%-8.03% 32.25B
+1.91%+4.97%+18.66%+60.85% 31.68B
+0.69%+8.72%+14.80%+30.86% 24.59B
-0.14%+11.99% - - 16.57B
+3.31%+6.20%+69.62%+127.82% 15.12B
-0.15%+2.15%+12.64%+17.55% 13.69B
-0.51%+2.85%+97.05%+91.58% 13.1B
Average +0.85%+7.36%+116.85%+106.81% 23.81B
Weighted average by Cap. +1.61%+7.40%+99.28%+134.79%

Financials

2026 *2027 *
Net sales 12.55M 11.02M 10.15M 9.45M 17.83M 1.19B 18.19M 122M 47.28M 586M 47.14M 46.12M 2.04B 16.32M 14.33M 13.19M 12.29M 23.18M 1.55B 23.65M 159M 61.47M 762M 61.29M 59.96M 2.65B
Net income -288M -253M -233M -217M -409M -27.4B -418M -2.8B -1.09B -13.45B -1.08B -1.06B -46.82B -303M -266M -245M -229M -431M -28.85B -440M -2.95B -1.14B -14.16B -1.14B -1.11B -49.28B
Net Debt -292M -256M -236M -220M -415M -27.76B -423M -2.84B -1.1B -13.63B -1.1B -1.07B -47.43B -221M -194M -178M -166M -314M -21B -320M -2.15B -832M -10.31B -829M -811M -35.87B
Logo Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.
Employees
193
Date Price Change Volume
26-07-01 US$17.98 -3.90% 1,675,538
26-06-30 US$18.71 -5.22% 5,799,149
26-06-29 US$19.74 +6.36% 4,215,703
26-06-26 US$18.56 +4.09% 12,573,933
26-06-25 US$17.83 -1.05% 7,190,474
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
18.71USD
Average target price
24.82USD
Spread / Average Target
+32.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RLAY Stock